+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Gene Editing Market - By Application, By Technology, and By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 - 2026

  • ID: 5143373
  • Report
  • July 2020
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
The global gene editing market, which accrued proceeds worth 4.02 (USD Billion) in 2019, is set to record the CAGR of nearly 14.6% over the period from 2020 to 2026. The report offers assessment and analysis of the gene editing market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Billion).


Gene editing is assisting in transformation of basic research in the life sciences and is projected to find plethora of applications in human & animal health, farming & food systems, and the bio-economy. Today, scientists can modify sequences of DNA through insertion or deletion of genes in cells of living organisms. Apparently, the current gene editing methods are safe, effective, and cost-effective and hence have found applications in array of industries. Specifically, two nuclease-based gene-editing technologies, TALE and CRISPR, help scientists to edit genomes with extraordinary precision in a shorter duration. Moreover, these gene editing techniques have provided exact & regulated was for changing crop & animal traits. Furthermore, nuclease-based gene editing is likely to bring revolution in agriculture sector and increase crop yield.

Furthermore, researchers are trying to modify immune cells or T-cells for preventing them from getting infected due to HIV. Scientists are developing various kinds of gene editing methods for treating hemophilia, and engineer T-cells to target & destroy cancer tissues.

Market Growth Drivers

Gene editing is creating a paradigm shift in biotechnology domain. Reportedly, gene editing techniques like CRISPR has the capability of influencing the fields of personalized medicine, cancer research, and healthcare. This, in turn, will built a strong platform for the growth of gene editing market within a span of next few years. Furthermore, gene editing is also used for disease modelling in human beings as well as in gene therapy. It is also utilized for treating heart ailments, viral diseases, inherited eye disorders, hematological ailments. In future, it is also possible to use gene editing tools in cancer immunotherapy, gene diagnostics, and screening of functional genes.

In nuclease-based gene editing, nucleases are used to edit genes. Apparently, nuclease-based gene editing technique finds a slew of applications in the field of biotechnology and is used widely in research & genetic trials as it is cost-effective, easy to perform, and fast. Reportedly, since last few years, TALEN and CRISPR nucleases have enhanced the speed and lowered the cost of gene editing procedures to a larger extent. They have been one of the most vital breakthroughs in the gene editing technologies and are likely to find massive utilization in medical, healthcare, and farming activities. This, in turn, will not only open new vistas of growth for nuclease-based gene editing market, but will favorably influence the gene editing industry over a long run.

Furthermore, nuclease-based gene editing is already being developed for human therapeutics, as a new approach to perform gene therapy and introducing or editing genes to cure diseases. Reportedly, growing progress in creation of programmable nucleases like zinc-finger nucleases, transcription activator-like effector nucleases or TALENs, and Cas9-related nucleases is projected to expedite the growth of gene editing market over the forecast timeline. Apparently, their derivative agents are used as gene editing tools for treating myriad human diseases.

Other very potential gene editing approaches are being developed in the field of immuno-oncology with engineered CAR-T cells directing immune system to fight and eliminate cancer cells. There is an extensive array of potential uses of gene editing techniques in biosynthesis of pharmaceuticals, biofuels, other high-value chemicals, biosensors, bioremediation, and in the food chain. Innovation in the bioeconomy will further augment the gene editing business growth in the near future.

According to the results presented by CRISPR Therapeutics & Vertex Pharmaceuticals before European Hematology Association in June 2020, it was demonstrated that two patients affected due to beta thalassemia and one subject suffering from sickle cell disorder did not require transfusion of blood after their stem cells in the bone marrow were gene edited by using CRISPR technique. This breakthrough is likely to encourage the development of new gene editing therapies for treating various kinds of hereditary diseases in the foreseeable future.

As per NCBI, most clinical utilization of CRISPR gene editing techniques has highlighted onex vivogene edition of cells succeeded by the re-introduction of these gene-edited cells again into the subject. Theex vivoediting method has proved to be highly effective for treating many diseases including cancers and sickle cell. However, gene editing can also be applied to diseases requiring cell alterationin vivo.

Moreover, with the rapid evolution of new gene editing procedures, long-lasting or permanent alleviation of genetic disorders through selective modifying of the human genes may become a possibility in the near future, thereby generating huge potential for not only enhancing human health, but also the lifespan of the human beings.

North America To Dominate Overall Market Expansion Over 2020-2026

The growth of the market in North America during the period from 2020 to 2026 is credited to massive acceptance of new gene editing methods in the research institutions in the countries like the U.S. Moreover, favorable laws in the countries like U.S. encouraging gene editing research activities will boost the regional market growth.

Key players influencing market growth include Sangamo Therapeutics, Inc., Lonza Group, Integrated DNA Technologies, Editas Medicine, New England Biolabs, Horizon Discovery Group, Thermo Fisher Scientific, CRISPR Therapeutics, Merck KgaA, GenScript Corporation, and OriGene Technologies.

The global gene editing market is segmented as follows:

By Application
  • Animal Genetic Engineering
  • Cell Line Engineering
  • Plant Genetic Engineering
  • Others
By End-User
  • Contract Research Organization (CRO)
  • Biotech & Pharma Companies
  • Research Institutes
By Technology
  • Zinc Finger Nucleases (ZFNs)
  • CRISPR/Cas9
  • Others
By Region
  • North America
  • The U.S.
  • Canada
  • Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Gene Editing Market, 2016–2026(USD Billion)
    • 2.2. Gene Editing Market: Snapshot
  • Chapter 3. Global Gene Editing Market– Industry Analysis
    • 3.1. Gene Editing Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. There is an extensive array of potential uses of gene editing techniques in biosynthesis of pharmaceuticals, biofuels, other high-value chemicals, biosensors, bioremediation, and in the food chain and this will propel the industry growth
      • 3.2.2. Growing progress in creation of programmable nucleases like zinc-finger nucleases, transcription activator-like effector nucleases or TALENs, and Cas9-related nucleases is projected to expedite the growth of gene editing market.
    • 3.3. Market Attractiveness Analysis
      • 3.3.1. Market attractiveness analysis By technology
      • 3.3.2. Market attractiveness analysis By Application
      • 3.3.3. Market attractiveness analysis By End-User
  • Chapter 4. Global Gene Editing Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Gene Editing Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New technology Type launches
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Gene Editing Market–technology Analysis
    • 5.1. Global Gene Editing Market overview: By technology
      • 5.1.1. Global Gene Editing Market share, By technology,2019 and 2026
      • 5.2.1. Global Gene Editing Market by ZINC FINGER NUCLEASES (ZFNS), , 2016–2026(USD Billion)
    • 5.3. CRISPR/CAS9
      • 5.3.1. Global Gene Editing Market by CRISPR/CAS9, 2016–2026(USD Billion)
    • 5.4. TALENS
      • 5.4.1. Global Gene Editing Market by TALENS, 2016–2026(USD Billion)
    • 5.5. Others
      • 5.5.1. Global Gene Editing Market by Others, 2016–2026(USD Billion)
  • Chapter 6. Global Flame Detector Market– Application Analysis
    • 6.1. Global Gene Editing Market overview: By Application
      • 6.1.1. Global Gene Editing Market share, By Application, 2019 and 2026
    • 6.2. Animal Genetic Engineering
      • 6.2.1. Global Gene Editing Market By Animal Genetic Engineering , 2016–2026(USD Billion)
      • 6.3.1. Global Gene Editing Market By CELL LINE ENGINEERING, 2016–2026(USD Billion)
    • 6.4. Plant Genetic Engineering
      • 6.4.1. Global Gene Editing Market By Plant Genetic Engineering, 2016–2026(USD Billion)
    • 6.5. Others
      • 6.5.1. Global Gene Editing Market By Others, 2016–2026(USD Billion)
  • Chapter 7. Global Flame Detector Market– End-User Analysis
    • 7.1. Global Gene Editing Market overview: By End-User
      • 7.1.1. Global Gene Editing Market share, By End-User , 2019 and 2026
    • 7.2. Contract Research Organization (CRO)
      • 7.2.1. Global Gene Editing Market By Contract Research Organization (CRO), 2016–2026(USD Billion)
    • 7.3. Biotech & Pharma Companies
      • 7.3.1. Global Gene Editing Market By Biotech & Pharma Companies, 2016–2026(USD Billion)
    • 7.4. Research Institutes
      • 7.4.1. Global Gene Editing Market By Research Institutes, 2016–2026(USD Billion)
  • Chapter 8. Company Profiles
    • 8.1. New England Biulabs
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. technology Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Thermo Fisher Scientific
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. technology Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. CRISPR Therapeutics
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. technology Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Merck KgaA
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. technology Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Development
    • 8.5. GenScript Corporation
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. technology Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Sangamo Therapeutics, Inc.
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. technology Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Editas Medicine
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. technology Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. Integrated DNA technologies
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. technology Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Lonza Group
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. technology Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
    • 8.10. Horizon Discovery Group
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. technology Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Development
    • 8.11. OriGene technologies
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. technology Portfolio
      • 8.11.4. Business Strategy
      • 8.11.5. Recent Development
Note: Product cover images may vary from those shown